Introduction
The burden of cancer disparities on African American and Hispanic populations has been well documented. [1] [2] [3] [4] [5] [6] [7] [8] It is our opinion that discoveries in precision medicine and basic science with the potential to improve the prognosis or treatment of cancer in affected individuals might be limited by the scarcity of research biospecimens from racial/ethnic minority populations. The availability of diverse samples is key to inclusive precision medicine. 9 For example, the triple-negative breast cancer subtype, defined by the absence of ER, PR, and ERBB2 (formerly HER2 or HER2/neu) expression, accounts for 10% to 20% of all breast cancer cases, with an uneven distribution among ethnicities. 10 In African American women, triple-negative breast cancer is nearly twice as prevalent as it is in European Americans, with some studies reporting triple-negative subtypes in up to 40% of all breast cancer cases among premenopausal African Americans. 10, 11 Consistent with this observation, epidemiological studies have shown substantial differences in rates of breast cancer mortality between racial groups. 5, 8, 12 For example, premenopausal African American women have a lower 5-year breast cancer-related survival rate than European American women (79.0% vs 91.0%, respectively), placing them at a higher risk of mortality despite an overall lower incidence of breast cancer. 12 This disparity may be due to the increased frequency of triple-negative breast cancer observed in African American women who typically present at a later disease stage and are more likely to have lymph-node metastases at similar tumor sizes. 13 Study findings have revealed that Hispanic women have a higher prevalence of ER-negative tumors compared with non-Hispanic women (36.2% vs 22.7%; P = .05) and an unexpectedly high proportion of ERBB2-positive tumors compared with non-Hispanic women (31.9% vs 14.3%; P < .01).
14 These findings, coupled with more recent data, suggest that considerable molecular differences in cancers may exist in various ethnic groups. 10 Because molecular features can be used for predicting cancer prognosis and therapeutic response, research focused on understanding the molecular features of cancers occurring in ethnic minorities is important.
Purpose
To address the lack of tissue-based studies for ethnic minorities with cancer, the Biospecimen/Biobanking Geographic Management Program (BMaP) was initiated by the National Cancer Institute's Center to Reduce Cancer Health Disparities. BMaP coordinated regional efforts focused on health disparities in cancer research, training, and care and was organized into 6 geographical regions within the United States. BMaP region 3 (BMaP-3), which makes up the southeastern region, consists of Alabama, Florida, Georgia, Louisiana, Mississippi, and Puerto Rico, and it included 9 partner institutions that created a collaborative network. A key goal for BMaP-3 was to develop a stateof-the-art network that could provide a foundation and infrastructure to adequately and continuously supply high-quality, multiethnic, human biospecimens for cancer research. Since 2015, the National Cancer Institute has reorganized and consolidated the regions into 6 regions, and the institutions previously in region 3 are now, at the time of publication, in Geographical Management of Cancer Health Disparities region 2.
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In 2014, members of the participating BMaP-3 institutions completed a comprehensive assessment tool that revealed a diversity of samples by race/ethnicity and cancer site were available as formalin-fixed, paraffin-embedded (FFPE) tumor samples or fresh-frozen samples (from 6 of 9 institutions). 16 In addition, 5 of the institutions had a tissue advisory/steering committee, thus providing the necessary infrastructure and expertise to build a network approach. This provided the basis for the design of a BMaP-3 pilot study to test the feasibility of developing and implementing a regional, web-based database of available biospecimens and collecting FFPE blocks to create unique tissue microarrays (TMAs) for health disparities in cancer research.
This pilot study represents a regional team, science-oriented approach for constructing and validating multi-institutional breast cancer TMAs from a racially and ethnically diverse population. Using the construction and validation of a breast cancer TMA as an example, we illustrate how a regional team, science-oriented approach can effectively leverage the tissue and database resources of multiple institutions to facilitate tissue-based studies for a minority cohort -a difficult challenge for single institutions alone.
Materials and Methods
The research conducted in this study was performed with tissue samples and patient data unlinked from patient identifiers. Approval or waiver of informed consent was obtained by the Institutional Review Boards of the 6 institutions contributing FFPE biospecimens and data to support this pilot study.
Collection and Management of Data
Cancer registry coding discrepancies were harmonized by adopting a standardized coding for each variable and systematically replacing prior coding with current coding using software R v2.15.2 (R Foundation for Statistical Computing, Vienna, Austria). Patient cases were removed from the data sets for any of the following reasons: younger than 18 years of age at diagnosis (n = 1), tumor marker and site-specific factor did not agree for either ER or PR status (n = 157), had a Spanish surname and unknown "Spanish Hispanic" vari-able (n = 17), or assigned a study identification number that already existed (n = 1). The original site-specific factor 16 was captured after the year 2010; therefore, the site-specific factor was manually derived from the tumor marker 1 ER assay, tumor marker 2 PR assay, and ERBB2 variables, with assignments of either
-. If the original site-specific factor 16 disagreed with the derived site-specific factor, then the entry was deemed unreliable and was deleted (n = 19).
Multi-Institutional, Web-Based Database
To ensure no changes were made to the data set originally merged by the biostatistician, the web-based data set was exported and a comparison of the webbased data set against the original merged data set was executed. Counts were also verified between both data sets. The aggregated data were posted on a website (http://labpages.moffitt.org/bmap3/Cancer%20Database/Cancer_Database.html [access restricted]) in the form of an output of descriptive statistics generated by SPSS (IBM, Armonk, NY). BMaP-3 public access database (PAD) has logging features enabled so that, in the event of improper data modification, the user account responsible, the data that were changed, and the time of the change can be identified and corrected in a timely manner. The governance model for the BMaP-3 PAD consists of 3 hierarchical user-access levels (administrator, data manager, and investigator), ranging from full to search access.
Archival Case Selection and Tissue Microarray Construction
Each archival tissue sample was categorized according to tumor expression of ER, PR, and ERBB2. For each case, optimal areas for inclusion as cores in the TMA were marked on the slides stained with hematoxylin and eosin by pathologists. When sufficient tumor tissue was available, 3 or fewer 1-mm cores from each selected donor block were punched and put into 8 TMAs 60 × 10 mm in size using Tissue Arrayer (Beecher Instruments, Sun Prairie, WI). Each TMA also included 1 sample of normal breast tissue. Cores from kidney, spleen, and tonsil, as well as melanoma, human breast cancer lines (MCF-7 and MDA231), human prostate adenocarcinoma cells (LNCaP), and human ovarian carcinoma cells (SK-OV-3), were included as reference cells/tissues.
Immunohistochemical Staining and Evaluation
All TMA slides were stained with hematoxylin and eosin and processed for whole-slide imaging. Each TMA slide was scanned using ScanScope XT (Aperio, Vista, CA) with a 20×/0.8 numerical aperture objective lens at a rate of 10 minutes per slide. Image analyses for stained TMAs were performed using Nuclear v9.1 (Aperio) to segment nuclei of various intensities. The captured hematoxylin and eosin stained images were made available to investigators at all participating institutions. The biomarker status obtained from cancer registry data was validated with immunostains for estrogen receptor (ER), progesterone receptor (PR), and erb-b2 receptor tyrosine kinase 2 (ERBB2) using the following antibodies from Ventana Medical Systems (Tucson, AZ): 790-4324 CONFIRM anti-ER (SP1), 790-2223 CONFIRM anti-PR (1E2), and 790-100 PATHWAY anti-HER2/Neu (4B5). Antigen retrieval and incubation times were optimized for each antibody as follows: 60-minute retrieval for ER and PR antibodies; 30-minute retrieval for ERBB2 antibodies; 32-minute incubation for the ER antibody; and 16-minute incubation for the PR and ERBB2 antibodies.
The Ventana Benchmark XT (Tucson, AZ) platform was used for all immunohistochemistry analyses. The Allred scoring system was used to score the ER and PR stains.
17 ERBB2 stains were scored in accordance with guidelines from the College of American Pathologists, which defines ERBB2-positive status by immunohistochemistry as protein overexpression. 18 The HR rules for the categorization of cases were: if either ER or PR is positive, then HR + ; if both are negative, then HR -; and if both ER and PR are missing, or if one is missing and the other is negative, then it was labeled as "missing."
Results

Building an Infrastructure
To ensure equitable governance for issues concerning human biospecimen research sponsored by BMaP-3, a Tissue Advisory Board was formed with representatives from all 9 BMaP-3 institutions. A collaboration agreement, signed by members of each of the 9 partner institutions, allowed data and tissue sharing between the partner institutions regardless of the ability of any individual institution to contribute samples. Once the infrastructure was established, the goal was to evaluate the feasibility of collecting FFPE tissue blocks and associated data and creating a web-based database and TMAs.
The first step in this pilot study was to choose a tumor type for the TMA. The BMaP-3 investigators chose breast cancer as the highest priority to address health disparities related to cancer in the southeastern United States and Puerto Rico. This decision was based on a variety of factors, including unpublished observations on the scarcity of breast TMAs from diverse populations described in the literature, lack of commercially available breast TMAs with associated patient data on race and ethnicity, the observed rates of incidence and mortality associated with breast cancer at the 6 contributing cancer sites, and the unpublished results of a multi-institutional survey of researcher needs for TMAs. 16 In addition, researchers specializing in breast cancer were surveyed to determine what type of breast cancer TMA is most needed for research. As shown in Fig 1, 29 
/ethnic groups, followed by a TMA based on 1 histological type of breast tissue in different racial/ethnic groups (26%), and a TMA based on 1 tumor, node, and metastasis pathology stage group in different racial/ethnic groups (14%).
Collection and Management of Cancer Registry Data
Deidentified American College of Surgeons cancer registry data from each institution served as the basis for the web-based database and for the selection of cases to be included in the TMA. Requests for data from cancer registries at each of the 9 partner institutions specified the following criteria for selecting cases: date range, 2001 to 2011 (to avoid using biospecimens that might be needed for clinical care), age at diagnosis (≥ 18 years of age), primary breast cancer only (no metastasis), and first-course surgery at the institution. In addition, because cases from minority populations were a priority for inclusion in the TMA, members at partnering institutions were asked to specifically retrieve patient data from African Americans and Hispanics/Latinos. The 17 data elements requested are described in Table 1 .
Cancer registry data sets were retrieved from 6 institutions, and a biostatistician harmonized the data sets. A total of 12,408 entries from 8,279 unique patients with breast cancer pathology were confirmed after merging the data sets. Deidentified information about breast cancer cases collected from the different cancer registries is available in BMaP-3 PAD (https:// apps.mathbiol.org/bmap [access restricted]).
Archival Case Selection and Tissue Microarray Construction
The data set was further analyzed for cases with invasive ductal carcinoma (IDC; histology selected by the Tissue Advisory Board) and then cross-tabulated by race/ethnicity and biomarker status (triple-negative,
. The demographical and clinical characteristics of the data from the breast cancer cases obtained from the 6 institutions are presented in Table 2 Respondents, % Fig 1. -Results of the breast cancer researcher survey (N = 61). A multiinstitutional, web-based poll was distributed to investigators in region 3 (currently region 2) institutions to assess the research interest regarding different kinds of breast TMAs. Survey responses were anonymous. As can be seen, the greatest need was for TMA based on biomarker status between different racial and ethnic groups. TMA = tissue microarray, TNM = tumor, node, metastasis.
IDC were tabulated according to biomarker status (site-specific factor 16) and by race/ethnicity (Table 3) . Although a large portion of cases were missing data, this analysis revealed that, in this cohort, African American women have a higher incidence of triplenegative breast cancer compared with white women, and Hispanic women have a higher incidence of HRnegative breast cancer compared with non-Hispanic women. These data, as well as data on breast cancer cases not included in the TMA, were incorporated into the BMaP-3 PAD web-based database.
FFPE blocks were requested from participating institutions, and 427 blocks from 427 unique patients with breast cancer were obtained. -, and triple negative) for each stain. Thereafter, the cancer registry data were reviewed, and 4 samples originally classified as triple negative were reclassified as either ERBB2 + or HR + . Several discrepancies were found between the cancer registry data and the TMA immunohistochemistry results. Specifically, for all racial/ethnic groups, the biomarker status obtained from the cancer registry data was 100% in concordance to the staining results for ERBB2 -cases. However, this was not true for the triple-negative cases (86.8% and 85.7% rates of accuracy for African Americans/whites and Hispanics, respectively), and concordance was much lower in the case of ERBB2 + staining (43.6% and 30.6% for African Americans/whites and Hispanics, respectively). This finding could be due to different factors such as tumor heterogeneity or loss of antigenicity (eg, some donor blocks were several years old). 19 These stains were scanned and quantified, and links to the images were made available upon request. Detailed information on the samples included on the TMA is posted on http://labpages.moffitt.org/bmap3/Cancer%20Database /Cancer_Database.html.
Discussion
This pilot study successfully accomplished the following goals:
• Creation of a regional infrastructure with an organizing framework for communications, processes for memorandums of understanding and Institutional Review Board approval from multiple institutions, and an established Tissue Advisory Board and related guidelines • Processes for retrieval and synchronization of data from multiple cancer registries into a single data set • Development of a collaborative model for optimizing TMA design considerations • Development and implementation of a web-based database of cancer registry cases All of these accomplishments demonstrate the overall feasibility of creating a unique, centralized, public resource for multiethnic biobanking and the collection of biospecimens. Given the large number of cases included in the web-based database and the amount of TMAs, this model demonstrates that no institution could have accomplished these outcomes alone. A primary benefit of this approach is that members of all the partner institutions are eligible to access the data and tissue resources regardless of their capabilities to contribute to the database or TMA. The first step in this pilot study was to select a tumor type for creation of the TMAs. We chose to focus on breast cancer as the highest priority to address health disparities related to cancer in the southeastern United States and Puerto Rico for a variety of reasons. This pilot study demonstrated the feasibility of collecting cancer registry data for more than 12,000 breast cancer cases and creating a web-based database. We were successful in creating a racially/ethnically diverse TMA from FFPEs representing 427 breast cancer cases. For validation of the TMAs, we focused on studying the characteristics of IDC among different racial/ethnic groups because the investigators from the BMaP-3 institutions identified these as an important area of investigation, given the known differences in incidence of triple-negative IDC among diverse populations.
The results of the biomarker analysis showed a higher incidence rate of triple-negative breast cancer among African American women compared with white women and a higher incidence rate of HR-negative breast cancer among Hispanic women compared with non-Hispanic women. These observations are consistent with the literature. 10, 14 However, our analysis is compromised by a large amount of missing data. Hines et al 14 showed that breast cancer among Hispanic women comprises a distinct spectrum of tumor subtypes compared with non-Hispanic white women. In that study, a diverse TMA based on biomarkers was created, allowing researchers to study potential molecular differences in triple-negative breast cancer in different racial/ethnic groups. 14 Although most institutions had compatible bioinformatics systems for the management of biospecimen data, these systems were used for fresh frozen samples. No single institution had a direct database for associated FFPE tissue data; thus, cancer registry data and pathology reports were the sources of data for cases likely to have tissues stored at the respective institution. When needed, data would have had to be abstracted from pathology reports -which was beyond the resources of this project. Our findings suggest that the idea of synchronizing pathology reports with cancer registry data should be pursued because pathology reports offer more complete and accurate information on biomarker data than is currently provided by a cancer registry.
Conclusions
We have created a model for collaboration. Through the contribution of formalin-fixed, paraffin-embedded blocks from the Minority Biospecimen/Biobanking Geographic Management Program for region 3 (BMaP-3) institutions, this project facilitated the creation of a robust research tool that would not be readily available if each institution worked independently. Moreover, each institution benefited from the collaboration and from the team approach to tackle a research/clinical issue common to all team members. It is expected that investigators at the partner institutions will utilize the web-based database on an ongoing basis for data analysis. This database is freely available with open access for the BMaP-3 investigators. We fully expect that the model and process for the work described herein could be applied and exported to other multi-institutional networks focused on a participatory approach to biobanking. We also demonstrated the feasibility of creating tissue microarrays from racially and ethnically diverse populations through the BMaP-3 partnership. This work was made possible by the infrastructure of this partnership, and it can serve as a model for other multiinstitutional networks focused on research utilizing human biospecimens. To date, these tissue microarrays of invasive ductal carcinoma have been released for 5 projects at 5 different institutions.
